Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab.

Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature (2010) 6.13

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med (2013) 5.72

Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res (2008) 2.52

Tolerogenic dendritic cells: cytokine modulation comes of age. Blood (2006) 2.51

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica (2008) 2.46

Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J (2005) 2.33

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood (2007) 2.31

Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica (2008) 2.20

DNMT1-interacting RNAs block gene-specific DNA methylation. Nature (2013) 2.04

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood (2011) 2.02

Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica (2009) 1.99

Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience. Acta Neurochir (Wien) (2012) 1.99

Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica (2012) 1.98

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood (2011) 1.96

ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood (2006) 1.95

Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood (2005) 1.88

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood (2003) 1.84

High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leuk Lymphoma (2012) 1.77

Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. Blood (2003) 1.76

Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood (2002) 1.68

Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol (2010) 1.66

Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect (2009) 1.64

The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood (2010) 1.63

Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study. Blood (2011) 1.62

Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood (2006) 1.60

Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood (2006) 1.57

Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood (2002) 1.57

Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica (2002) 1.56

Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood (2002) 1.55

Inhibition of telomerase in the endothelial cells disrupts tumor angiogenesis in glioblastoma xenografts. Int J Cancer (2008) 1.55

Molecular analysis of immunoglobulin variable genes in human immunodeficiency virus-related non-Hodgkin's lymphoma reveals implications for disease pathogenesis and histogenesis. Haematologica (2008) 1.54

Mutations of the BIK gene in human peripheral B-cell lymphomas. Genes Chromosomes Cancer (2003) 1.50

Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia. Leuk Res (2006) 1.48

Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. Leuk Lymphoma (2013) 1.47

The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol (2006) 1.47

Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J Clin Oncol (2013) 1.47

Endothelial progenitor cell trafficking in human immunodeficiency virus-infected persons. AIDS (2010) 1.45

Primary plasma cell leukemia followed by testicular plasmacytoma. Int J Hematol (2011) 1.44

Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. Leuk Res (2011) 1.42

Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic stem-cell transplantation: report from the working conference on iron chelation of the Gruppo Italiano Trapianto di Midollo Osseo. Am J Hematol (2011) 1.42

[Myeloproliferative disorders due to the use of gasoline as a solvent: report of three cases]. Med Lav (2005) 1.42

Endothelial progenitor cells in HIV-positive patients: what are we talking about? J Acquir Immune Defic Syndr (2013) 1.42

Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. J Immunol (2005) 1.40

Protein kinase gene expression profiling and in vitro functional experiments identify novel potential therapeutic targets in adult acute lymphoblastic leukemia. Cancer (2010) 1.40

Comparison of ZAP-70/Syk mRNA levels with immunoglobulin heavy-chain gene mutation status and disease progression in chronic lymphocytic leukemia. Haematologica (2005) 1.40

Intravascular large B cell lymphoma: when lymphoma is suspected but routine diagnostic work-up is negative. Leuk Lymphoma (2009) 1.37

CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood (2007) 1.35

Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood (2002) 1.35

Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha. Eur J Immunol (2004) 1.29

The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience. Am J Hematol (2011) 1.27

The haematocrit and platelet target in polycythemia vera. Br J Haematol (2006) 1.25

Chordoma of the skull base: predictors of tumor recurrence. J Neurosurg (2003) 1.24

Endogenous G-CSF and CD34+ cell mobilization after acute myocardial infarction. Int J Cardiol (2005) 1.23

Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res (2009) 1.21

Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res (2010) 1.21

Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood (2007) 1.19

The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma. Clin Cancer Res (2011) 1.18

Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood (2005) 1.18

Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant (2010) 1.17

Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood (2006) 1.17

Role of the life span determinant P66(shcA) in ethanol-induced liver damage. Lab Invest (2008) 1.15

Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica (2009) 1.15

Molecular histogenesis of plasmablastic lymphoma of the oral cavity. Br J Haematol (2002) 1.10

Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer (2013) 1.09

Mast cell leukemia: a report of ten cases. Ann Hematol (2008) 1.09

Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer (2010) 1.07

Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis. Int J Cancer (2002) 1.07

High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol (2013) 1.07

Can a gene-expression classifier with high negative predictive value solve the indeterminate thyroid fine-needle aspiration dilemma? Cancer Cytopathol (2013) 1.06

Is morphology alone able to predict BRAF-mutated malignancies on thyroid FNAC? Virchows Arch (2014) 1.06

Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior. Prostate (2010) 1.06

Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood (2011) 1.05

A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis. Haematologica (2008) 1.04

Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis (2013) 1.03

Epidemiology of HCV infection in the general population: a survey in a southern Italian town. Am J Gastroenterol (2009) 1.03

Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer (2011) 1.02

Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. Blood Cells Mol Dis (2010) 1.01

Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma. Clin Cancer Res (2005) 1.01

Methylenetetrahydrofolate reductase genotypes do not play a role in acute lymphoblastic leukemia pathogenesis in the Italian population. Haematologica (2004) 1.00

Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol (2006) 1.00